Page last updated: 2024-12-05

primaquine phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6135
CHEMBL ID43128
SCHEMBL ID41096
MeSH IDM0017575

Synonyms (98)

Synonym
1,4-pentanediamine, n(sup 4)-(6-methoxy-8-quinolinyl)-, (+-)-, phosphate (1:2)
1,4-pentanediamine, n4-(6-methoxy-8-quinolinyl)-, phosphate (1:2)
ccris 1946
8-((4-amino-1-methylbutyl)amino)-6-methoxyquinoline phosphate (1:2)
8-((4-amino-1-methylbutyl)amino)-6-methoxyquinoline diphosphate
einecs 200-560-8
1,4-pentanediamine, n(sup 4)-(6-methoxy-8-quinolinyl)-, phosphate (1:2)
(+-)-8-((4-amino-1-methylbutyl)amino)-6-methoxyquinoline phosphate (1:2)
primaquine bis(phosphate)
quinoline, 8-((4-amino-1-methylbutyl)amino)-6-methoxy-, phosphate (1:2)
nsc 149765
PRESTWICK_406
NCGC00016284-01
cas-63-45-6
63-45-6
nsc-149765
primaquine diphosphate
primaquine phosphate
D02126
primaquine (tn)
primaquine phosphate (jan/usp)
primaquine bisphosphate, 98%
NCGC00094767-01
NCGC00094767-02
SPECTRUM1500500
phosphate, primaquine
diphosphate, primaquine
HMS2092A19
malquine
CHEMBL43128
primaquini diphosphas
primachine phosphate
HMS502I08
HMS1569O14
HMS1920J18
HMS2096O14
dtxsid6045248 ,
tox21_110350
dtxcid4025248
S4237
primaquine bisphosphate
CCG-40283
primaquine phosphate [usp]
unii-h0982hf78b
h0982hf78b ,
primaquine phosphate [jan]
quinoline, 8-((4-amino-1-methylbutyl)amino)-6-methoxy-, diphosphate
primaquine phosphate [orange book]
8-(4-amino-1-methylbutylamino)-6-methoxyquinoline diphosphate
primaquine phosphate [usp-rs]
primaquine phosphate [mart.]
primaquine phosphate [vandf]
primaquine phosphate [who-dd]
camden
84902-21-6
primaquini diphosphas [who-ip latin]
primaquine diphosphate [mi]
primaquine phosphate [usp monograph]
primaquine diphosphate [who-ip]
primaquine diphosphate [ep monograph]
SCHEMBL41096
n-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; bis(phosphoric acid)
tox21_110350_1
CS-3875
GJOHLWZHWQUKAU-UHFFFAOYSA-N
8-?(4-?amino-?1-?methylbutylamino)?-?6-?methoxyquinoline diphosphate salt
HY-12651
primaquine (diphosphate)
AKOS026749962
sr-05000001864
SR-05000001864-7
primaquine phosphate, united states pharmacopeia (usp) reference standard
HMS3652B19
SR-05000001864-1
SR-05000001864-3
primaquine diphosphate, european pharmacopoeia (ep) reference standard
HMS3713O14
8-(4-amino-1-methylbutylamino)-6-methoxyquinolinediphosphate
SW196647-3
primaquine phosphate;primaquine bisphosphate
sn13272 diphosphate
E75742
8-(4-amino-1-methylbutylamino)-6-methoxyquinoline diphosphate salt
mfcd00013166
n4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine bis(phosphate)
AS-13148
ibscreen-bb bb_sc-03079
Q27279400
n4-(6-methoxyquinolin-8-yl)pentane-1,4-diaminebis(phosphate)
EN300-119547
n4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; bis(phosphoric acid)
1,4-pentanediamine, n^4-(6-methoxy-8-quinolinyl)-, phosphate (1:2)
(4rs)-n4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine diphosphate
primaquine phosphate (mart.)
primaquine phosphate (usp-rs)
primaquine phosphate (usp monograph)
primaquine phosphate (usp)
primaquine diphosphate (ep monograph)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.12540.177814.390939.8107AID2147
acetylcholinesteraseHomo sapiens (human)Potency43.64860.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.04220.006038.004119,952.5996AID1159521
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency10.74800.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency3.75780.000714.592883.7951AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency8.10190.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.02510.01237.983543.2770AID1346984
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.87750.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency12.03560.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency12.12960.001530.607315,848.9004AID1224841; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.91480.000229.305416,493.5996AID1259248; AID743079; AID743080; AID743091
activating transcription factor 6Homo sapiens (human)Potency3.37800.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency14.92480.010039.53711,122.0200AID1567; AID1568; AID1573
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency14.29990.000323.4451159.6830AID743065; AID743067
caspase-1 isoform alpha precursorHomo sapiens (human)Potency31.62280.000311.448431.6228AID900
Cellular tumor antigen p53Homo sapiens (human)Potency12.74480.002319.595674.0614AID651631
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Potency22.38720.794312.269331.6228AID1568
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)100.00000.00011.076810.0000AID1575185
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID116784Mean survival time of Plasmodium berghei infected mice (Mus musculus) after administration of single dose of 160 mg/kg intravenously1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial activity of 8-[(1-alkyl-4-aminobutyl)amino]-6-methoxy-4-methylquinolines.
AID1353266Selectivity index, ratio of IC50 for rat L6 cells to IC50 for erythrocytic stage of Plasmodium falciparum NF542018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID685500HARVARD: Cytotoxicity in HepG2 cell line2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID1147577Antimalarial activity against Plasmodium cynomolgi infected in monkey assessed as curative activity without disease relapses until 90 days at 0.75 mg/kg, po by radical curative monkey test1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis of 2-benzyloxy and 2-benzylthio analogues of primaquine as potential antimalarials.
AID1353264Antiplasmodial activity against erythrocytic stage of Plasmodium falciparum NF54 assessed as reduction in [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting method2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID116927Mean survival time of Plasmodium berghei infected mice (Mus musculus) after administration of single dose of 80 mg/kg intravenously1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial activity of 8-[(1-alkyl-4-aminobutyl)amino]-6-methoxy-4-methylquinolines.
AID1353272Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID116923Mean survival time of Plasmodium berghei infected mice (Mus musculus) after administration of single dose of 20 mg/kg intravenously1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial activity of 8-[(1-alkyl-4-aminobutyl)amino]-6-methoxy-4-methylquinolines.
AID1511325Antiplasmodial activity against asexual chloroquine sensitive blood stage Plasmodium falciparum 3D7 measured as HRP2 levels after 3 days by ELISA2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Primaquine homodimers as potential antiplasmodial and anticancer agents.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1511326Antiplasmodial activity against asexual chloroquine resistant blood stage Plasmodium falciparum Dd2 measured as HRP2 levels after 3 days by ELISA2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Primaquine homodimers as potential antiplasmodial and anticancer agents.
AID1147578Antimalarial activity against Plasmodium cynomolgi infected in monkey assessed as curative activity without disease relapses until 90 days at 0.375 mg/kg, po by radical curative monkey test1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis of 2-benzyloxy and 2-benzylthio analogues of primaquine as potential antimalarials.
AID120274Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 320 mg/kg and activity expressed as toxic deaths on days 2-51985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID1147584Antimalarial activity against Plasmodium cynomolgi infected in monkey assessed as relapses day at 0.375 mg/kg, po1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis of 2-benzyloxy and 2-benzylthio analogues of primaquine as potential antimalarials.
AID111936Mean survival time of mice(Plasmodium berghei) at a dose of 80 mg/kg, total no. of mice = 51985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID133609Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) test (five mice (Mus musculus))80 mg/kg (X 1)1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID126159Cures in sporozoite-induced Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) on 1 mg/kg/day peroral dose after 7 days, n=21982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID129410Number of animals found toxic out of five mice (Mus musculus) infected with Plasmodium berghei at 640 mg/kg(X 1) peroral administration1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID330904Binding affinity to human ORM1 at 37 degC by induced circular dichroism method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein.
AID129407Number of animals found toxic out of five mice (Mus musculus) infected with Plasmodium berghei at 160 mg/kg(X 1)peroral administration1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID1511327Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Primaquine homodimers as potential antiplasmodial and anticancer agents.
AID133605Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) test (five mice (Mus musculus)) 40 mg/kg (X 1)1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID116925Mean survival time of Plasmodium berghei infected mice (Mus musculus) after administration of single dose of 40 mg/kg intravenously1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial activity of 8-[(1-alkyl-4-aminobutyl)amino]-6-methoxy-4-methylquinolines.
AID1353269Cytotoxicity against human SW620 cells assessed as growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID1353273Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID1353275Cytotoxicity against human MCF7 cells assessed as cell growth at 10 uM after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID1402133Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue-based assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Primaquine hybrids as promising antimycobacterial and antimalarial agents.
AID1402130Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 after 7 days by Alamar Blue assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Primaquine hybrids as promising antimycobacterial and antimalarial agents.
AID1353268Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID1511328Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Primaquine homodimers as potential antiplasmodial and anticancer agents.
AID1402131Antimycobacterial activity against Mycobacterium avium complex CIT19/06 clinical isolate after 5 days by Alamar Blue assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Primaquine hybrids as promising antimycobacterial and antimalarial agents.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1353274Cytotoxicity against human Capan1 cells assessed as growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID120275Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 640 mg/kg and activity expressed as toxic deaths on days 2-51985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID133606Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) test (five mice (Mus musculus)) at a dose of 160 mg/kg (X 1)1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID1147581Antimalarial activity against Plasmodium cynomolgi infected in monkey assessed as relapses day at 0.5 mg/kg, po1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis of 2-benzyloxy and 2-benzylthio analogues of primaquine as potential antimalarials.
AID330903Binding affinity to human AAG at 37 degC by induced circular dichroism method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein.
AID1511329Antiproliferative activity against human H460 cells measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Primaquine homodimers as potential antiplasmodial and anticancer agents.
AID685503HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID1353265Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 70 hrs by Alamar blue assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID1353271Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID1353267Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID133604Suppressive antimalarial activity against Plasmodium berghei in Rane mice (Mus musculus) test (five mice (Mus musculus)) 20 mg/kg (X 1)1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID116924Mean survival time of Plasmodium berghei infected mice (Mus musculus) after administration of single dose of 320 g/kg intravenously1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial activity of 8-[(1-alkyl-4-aminobutyl)amino]-6-methoxy-4-methylquinolines.
AID685501HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID1353279Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10 uM cotreated with G6PD inhibitor 6-AN after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID129408Number of animals found toxic out of five mice (Mus musculus) infected with Plasmodium berghei at 320 mg/kg(X 1) peroral administration1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID1575185Inhibition of HIV1 reverse transcriptase assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 30 mins by scintillation counting method2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Multiple weak intercalation as a strategy for the inhibition of polymerases.
AID1353270Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
AID1511324Antiplasmodial activity against liver stage luciferase expressing Plasmodium berghei sporozoites infected in human Huh7 cells preincubated with host cells for 1 hr followed by plasmodium infection at 1 and 10 uM2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Primaquine homodimers as potential antiplasmodial and anticancer agents.
AID126154Cures in sporozoite-induced Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) on 1.3 mg/kg/day peroral dose after 7 days, n=61982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID116926Mean survival time of Plasmodium berghei infected mice (Mus musculus) after administration of single dose of 640 mg/kg intravenously1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial activity of 8-[(1-alkyl-4-aminobutyl)amino]-6-methoxy-4-methylquinolines.
AID1511330Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Primaquine homodimers as potential antiplasmodial and anticancer agents.
AID228953Molar primaquine Index value of compound was determined1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID1402132Antimycobacterial activity against Mycobacterium avium subsp. paratuberculosis CIT03 clinical isolate after 11 days by Alamar Blue assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Primaquine hybrids as promising antimycobacterial and antimalarial agents.
AID120273Antimalarial activity against Plasmodium berghei in mice (Mus musculus) at a dose of 160 mg/kg and activity expressed as toxic deaths on days 2-51985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
4-substituted 5-[m-(trifluoromethyl)phenoxy]primaquine analogues as potential antimalarial agents.
AID126158Cures in sporozoite-induced Plasmodium cynomolgi infected Rhesus monkeys (Macaca mulatta) on 0.316 mg/kg/day peroral dose after 7 days, n=21982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (22.22)18.7374
1990's0 (0.00)18.2507
2000's1 (5.56)29.6817
2010's11 (61.11)24.3611
2020's2 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.42 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index104.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]